Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
For the latest QIDP listing, please click HERE As of Oct. 9, 2014, there were by my accounting 30 compounds with QIDP designation. Here is the break-down: 31 compounds with QIDP designation 29 antibacterials, 2 antifungals 22 systemically active, 9 for topical administration 13 in Phase 3, 9 in Phase Continue reading QIDP Drugs: Here They Are, All of Them
Preclinical and early clinical development is expensive enough already for VC companies but it gets really expensive in Phase 3. Hence, not surprisingly, few small companies tackle Phase 3 programs on their own. Unless an ‘angel investor’ with deep pockets commits to the compound and assures continuity of development, the Continue reading The Difficult Transition Into Phase 3
The pleuromutilins are a relatively ‘old’ class of antibiotics that have seen much use in veterinary but not in human medicine. According to EMA, Tiamulin is an “essential antibiotic” for the control of dysentery in pigs which is caused by Brachyspira hyodysenteriae, a macrolide-resistant pathogen.[1] Retapamulin / Altabax® was introduced Continue reading BC-3781 Passes Phase 2 with Flying Colors, Readies for Phase 3